# Transcriptomic analysis reveals the impact of concurrent, resistance, and endurance training on skeletal muscle

**Authors:** Longfei Zhao, Huangyan Li, Dongli Li, Li Luo, Shiliang Hu, Donald Gullberg, Donald Gullberg, Donald Gullberg

PMC · DOI: 10.1371/journal.pone.0340309 · 2026-02-04

## TL;DR

This study compares how different types of exercise affect muscle at the genetic level, finding that all types share some common changes but also have unique effects.

## Contribution

The study identifies shared and modality-specific transcriptomic responses to concurrent, resistance, and endurance training in skeletal muscle.

## Key findings

- All training modalities activated extracellular matrix (ECM) remodeling pathways.
- Concurrent training preserved strength gains but reduced anaerobic power improvements.
- Resistance and endurance training uniquely activated specific gene networks like COL1A1/COL1A2 and SPARC/ASPN.

## Abstract

The shared and divergent molecular mechanisms underlying skeletal muscle adaptation to different exercise modalities are not fully understood. This study aimed to compare the physiological and transcriptomic responses to 12 weeks of concurrent (CET), resistance (RES), or endurance (END) training in healthy males. While all groups exhibited similar increases in lean body mass, RES and END elicited distinct functional improvements in maximal strength and aerobic capacity, respectively. Notably, CET preserved strength gains comparable to RES but showed a blunted improvement in anaerobic power. Transcriptomic analyses revealed both common and modality-specific signatures. Although the number of differentially expressed genes varied across groups (CET: 392; RES: 17; END: 49), enrichment analyses consistently identified the engagement of extracellular matrix (ECM) organization pathways. Gene set enrichment analysis further demonstrated a universal activation of ECM remodeling and an inhibition of translation initiation processes post-training. Weighted gene co-expression and protein-protein interaction network analyses pinpointed core genes associated with each modality, including COL1A1/COL1A2 for CET and END, and SPARC/ASPN for RES. Regulatory network predictions implicated the miR-29 family and JUN as potential co-regulators of collagen-related genes. In conclusion, this integrated analysis establishes ECM remodeling as a fundamental transcriptional response supporting exercise-induced hypertrophy common to diverse training modalities, while simultaneously identifying distinct gene regulatory networks that underlie their divergent functional outcomes.

## Linked entities

- **Genes:** COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278], SPARC (secreted protein acidic and cysteine rich) [NCBI Gene 6678], ASPN (asporin) [NCBI Gene 54829], JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725]

## Full-text entities

- **Genes:** COL6A1 (collagen type VI alpha 1 chain) [NCBI Gene 1291] {aka BTHLM1, BTHLM1A, OPLL, UCHMD1, UCHMD1A}, PI16 (peptidase inhibitor 16) [NCBI Gene 221476] {aka CD364, CRISP9, MSMBBP, PSPBP}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, TFAP2A (transcription factor AP-2 alpha) [NCBI Gene 7020] {aka AP-2, AP-2alpha, AP2TF, BOFS, TFAP2}, PRSS50 (serine protease 50) [NCBI Gene 29122] {aka CT20, TSP50}, LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, LAMB1 (laminin subunit beta 1) [NCBI Gene 3912] {aka CLM, LIS5, LKBMH, LUCAO}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, MYOC (myocilin) [NCBI Gene 4653] {aka GLC1A, GPOA, JOAG, JOAG1, TIGR}, CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, CALML6 (calmodulin like 6) [NCBI Gene 163688] {aka CAGLP}, COL5A1 (collagen type V alpha 1 chain) [NCBI Gene 1289] {aka EDSC, EDSCL1, FMDMF}, NID2 (nidogen 2) [NCBI Gene 22795] {aka NID-2}, SPARC (secreted protein acidic and cysteine rich) [NCBI Gene 6678] {aka BM-40, OI17, ON, ONT}, CFD (complement factor D) [NCBI Gene 1675] {aka ADIPSIN, ADN, DF, PFD}, COL4A1 (collagen type IV alpha 1 chain) [NCBI Gene 1282] {aka BSVD, BSVD1, COL4A1s, PADMAL, RATOR}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, GPR166P (G protein-coupled receptor 166, pseudogene) [NCBI Gene 442206] {aka GPCR, PGR9}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, LUM (lumican) [NCBI Gene 4060] {aka LDC, SLRR2D}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, LMOD1 (leiomodin 1) [NCBI Gene 25802] {aka 1D, 64kD, D1, MMIHS3, SM-LMOD, SMLMOD}, MIR29A (microRNA 29a) [NCBI Gene 407021] {aka MIRN29, MIRN29A, hsa-mir-29, hsa-mir-29a, miRNA29A, mir-29a}, VCL (vinculin) [NCBI Gene 7414] {aka CMD1W, CMH15, HEL114, MV, MVCL, VINC}, LAMA4 (laminin subunit alpha 4) [NCBI Gene 3910] {aka CMD1JJ, LAMA3, LAMA4*-1}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, PTGDS (prostaglandin D2 synthase) [NCBI Gene 5730] {aka L-PGDS, LPGDS, PDS, PGD2, PGDS, PGDS2}, ARL5B (ARF like GTPase 5B) [NCBI Gene 221079] {aka ARL8}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, CYP4B1 (cytochrome P450 family 4 subfamily B member 1) [NCBI Gene 1580] {aka CYPIVB1, P-450HP}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, RAB7B (RAB7B, member RAS oncogene family) [NCBI Gene 338382] {aka RAB7}, SLC25A19 (solute carrier family 25 member 19) [NCBI Gene 60386] {aka DNC, MCPHA, MTPPT, MUP1, THMD3, THMD4}, MYH6 (myosin heavy chain 6) [NCBI Gene 4624] {aka ASD3, CMD1EE, CMH14, MYHC, MYHCA, SSS3}, LOXL2 (lysyl oxidase like 2) [NCBI Gene 4017] {aka LOR, LOR2, WS9-14}, HTT (huntingtin) [NCBI Gene 3064] {aka HD, IT15, LOMARS}, MIR29C (microRNA 29c) [NCBI Gene 407026] {aka MIRN29C, miRNA29C, mir-29c}, MYH1 (myosin heavy chain 1) [NCBI Gene 4619] {aka HEL71, MYHSA1, MYHa, MyHC-2X/D, MyHC-2x}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, THBS4 (thrombospondin 4) [NCBI Gene 7060] {aka TSP-4, TSP4}, OGN (osteoglycin) [NCBI Gene 4969] {aka OG, OIF, SLRR3A}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, MSTN (myostatin) [NCBI Gene 2660] {aka GDF8, MSLHP}, DRC8 (dynein regulatory complex subunit 8) [NCBI Gene 84288] {aka CFAP200, EFCAB2}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ASPN (asporin) [NCBI Gene 54829] {aka OS3, PLAP-1, PLAP1, SLRR1C}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}
- **Diseases:** VCP-associated disease (MESH:D004194), muscle hypertrophy (MESH:C536106), hypertrophy (MESH:D006984), inflammatory (MESH:D007249), musculoskeletal injuries (MESH:D009140), fatigue (MESH:D005221), ORCID iD (MESH:C535742), muscle wasting (MESH:D009133)
- **Chemicals:** oxygen (MESH:D010100), fatty acid (MESH:D005227), prostaglandin (MESH:D011453), CET (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12871994/full.md

---
Source: https://tomesphere.com/paper/PMC12871994